EMPLOYMENT AGREEMENTEmployment Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • Delaware
THIS AGREEMENT is made and entered into effective as of April 1, 2012 by and between AntriaBio, Inc. a Delaware corporation, having an address of 55 Broad St., 19th Fl, New York, NY (“AntriaBio” or the “Company”), and Sankaram Mantripragada (the “Executive”).
ANTRIABIO DELAWARE, INC. STOCK OPTION CERTIFICATE Right to Purchase 3,500,000 Shares of Common Stock Exercise Price: $0.75 per ShareAntriaBio, Inc. • February 6th, 2013 • Services-business services, nec • Delaware
THIS CERTIFIES THAT, for value received, Nevan Elam (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the Vesting Date (as defined below) and at or prior to the close of business on January 30, 2018 (the “Expiration Date”), but not thereafter, to subscribe for and purchase from AntriaBio Delaware, Inc., a Delaware corporation (the “Company”), up to 3,500,000 fully paid and nonassessable shares of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”) at the Exercise Price (as defined herein). The Holder agrees that this certificate is for the Stock Option agreed to in the signed Employment Agreement between the Holder and the Company.
PROFORMA COMBINED FINANCIAL STATEMENTSProforma Combined Financial Statements • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec
On January 30, 2013, AntriaBio, Inc. (the “Company”) entered into a share exchange and reorganization agreement (the “Share Exchange and Reorganization Agreement”) dated January 14, 2013, by and among the Company, AntriaBio Delaware, Inc., a Delaware corporation (“AntriaBio Delaware”), and the beneficial stockholders of AntriaBio Delaware (the “AntriaBio Stockholders”), pursuant to which the AntriBio Stockholders agreed to exchange all of the outstanding capital stock AntriaBio Delaware (the “AntriaBio Capital Stock”) for an aggregate of 35,284,000 shares of the Company’s common stock representing approximately 88% of the Company’s issued and outstanding capital stock giving effect to such issuance and the other transactions described herein. As a result of such transaction, AntriaBio Delaware shall become a wholly-owned subsidiary of the Company. In connection with the Share Exchange and Reorganization Agreement, Tungsten 74, LLC, the majority stockholder of the Company agreed to deli
ContractShare Exchange and Reorganization Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • New York
SHARE EXCHANGE AND REORGANIZATION AGREEMENT, dated as of January 31, 2013 (the “Agreement”), among ANTRIABIO DELAWARE, INC., a Delaware corporation (“AntriaBio”); ANTRIABIO, INC., a Delaware corporation (“PublicCo”) and THE BENEFICIAL STOCKHOLDERS OF ANTRIABIO IDENTIFIED IN SCHEDULE A HERETO (the “AntriaBio Stockholders”).
ASSET PURCHASE AGREEMENT by and between ANTRIABIO, INC. and PR PHARMACEUTICALS, INC. Dated as of October 5, 2012Asset Purchase Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • Colorado
CONSULTANT AGREEMENTConsultant Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • Colorado
This Agreement is entered into as of July 1st, 2012, by and between AntriaBio, Inc., a Delaware Corporation, hereinafter referred to as COMPANY, and Hoyoung Huh, of Hannol Healthcare & Innovation, LLC, hereinafter referred to as Consultant.
ADVISORY AGREEMENTAdvisory Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • Delaware
This Advisory Agreement (“Agreement”) is effective as of July 2, 2012 by and between AntriaBio, Inc., a company incorporated under the laws of Delawre (“Client”) and Konus Advisory Group, Inc., a Delaware corporation (“KAG”), for the purpose of setting forth the terms and conditions by which the Client will acquire KAG’s services.
